FDA approves Amgen biosimilar of J&J's Remicade

The FDA approved Amgen's drug, Avsola, a biosimilar of Johnson & Johnson's Remicade, the company announced. 

Avsola is designed to treat rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. 

Avsola is now the fourth FDA-approved biosimilar for Remicade, following Pfizer's Ixifi, Merck's Renflexis, and Celltrion's Inflectra. 

Amgen, which announced the approval Dec. 6, did not say when Avsola would be available for sale. 

Read the full news release here

More articles on pharmacy:
UnitedHealth to acquire struggling specialty pharmacy
Pharmaceutical layoffs up nearly 6% from last year
Larger chunk of hospital drug spending going toward cancer treatments, study finds

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers